4SC AG: Patient Recruitment Completed for Phase IIa Clinical Trial
German drug company 4SC AG said it had completed patient recruitment for the Phase IIa clinical trial with its drug candidate SC12267 for the treatment of patients suffering from rheumatoid arthritis.
According to 4SC AG, SC12267 is a new type of small molecular active agent from the class of DMARDs used for treatment of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The substance works as a highly selective inhibitor in the biosynthesis of pyrimidine, which inhibits the proliferation of rapidly proliferating cells.
The three-tiered, placebo-controlled study is designed to give patients SC12267 twice daily over a three-month period and tested for tolerance and clinical efficacy. The study is being carried out in 13 centers across Germany, Poland and Serbia, the company said.
According to the company, study results are expected in the fourth quarter.